↓ Skip to main content

Chinese herbal medicine granules (PTQX) for children with moderate to severe atopic eczema: study protocol for a randomised controlled trial

Overview of attention for article published in Trials, July 2015
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
62 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Chinese herbal medicine granules (PTQX) for children with moderate to severe atopic eczema: study protocol for a randomised controlled trial
Published in
Trials, July 2015
DOI 10.1186/s13063-015-0806-y
Pubmed ID
Authors

Sherman X. Gu, Anthony L. Zhang, Meaghan E. Coyle, Xiumei Mo, George B. Lenon, Noel E. Cranswick, DaCan Chen, Charlie C. Xue

Abstract

Atopic eczema or atopic dermatitis is a chronic inflammatory skin disease. Current conventional medical treatment for moderate and severe atopic eczema is not satisfactory. There is promising evidence derived from randomised clinical trials to support the clinical use of Chinese herbal medicine in the management of atopic eczema. However, the available evidence is compromised by the high risk of bias associated with most of the included trials. Therefore, well-designed and adequately powered randomised clinical trials are needed. The primary aim of this trial is to evaluate the efficacy and safety of oral ingestion of an oral Chinese herbal formula (Pei Tu Qing Xin granules; PTQX) in children aged between 6 and 16 years with moderate to severe atopic eczema. We have designed a randomised, double-blind, placebo-controlled, two-arm, parallel clinical trial with 12 weeks of treatment and a 4-week follow-up period. A pilot study with 30 participants will be conducted at the RMIT University in Australia to determine the feasibility of the full-scale randomised clinical trial (N = 124). Eczema Area and Severity Index score will be the primary outcome. Secondary outcome measures include change in symptoms using the Patient-Oriented Eczema Measure, the Children's Dermatology Life Quality Index and the use of concomitant medicines. Safety parameters include report of adverse events and pathology tests during the trial period. Key elements for conducting a high-quality randomised clinical trial have been addressed in this protocol. Findings from the proposed trial will provide critical evidence regarding Chinese herbal medicine treatment for atopic eczema. Australian New Zealand Clinical Trials Registry Identifier: ACTRN12614001172695 . Date of Registration: 7 November 2014.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 62 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 15%
Student > Bachelor 8 13%
Researcher 8 13%
Librarian 3 5%
Student > Postgraduate 2 3%
Other 7 11%
Unknown 25 40%
Readers by discipline Count As %
Medicine and Dentistry 18 29%
Nursing and Health Professions 8 13%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Unspecified 2 3%
Mathematics 1 2%
Other 4 6%
Unknown 27 44%